Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Catalyst Biosciences
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04548791CT.gov Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders | — | Terminated | — | — | — |
NCT03407651CT.gov Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hemophilia A
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Coagulation Factor Viia Variant (this asset) | Catalyst Biosciences | P2 | B · 59 |
| Turoctocog Alfa | Novo Nordisk A/S | P4 | A |
| Eptacog Alfa (Activated) | AryoGen Pharmed Co. | P4 | A |
| Rurioctocog Alfa Pegol | Takeda | P4 | BBB |
| Immunoglobulin G4 [230-Proline,De-449-Lysine], Anti-(Human Blood-Coagulation Factor Ix)(Human Clone 0365-0001-9985 ?4-Chain), Disulfide With Human Clone 0365-0001-9985 ?-Chain, (228?226?),(231?229?)-Bis(Disulfide) With Anti-(Human Blood-Coagulation Factor X) Immunoglobulin G4 [228-Proline,405-Leucine,409-Lysine,De-447-Lysine] (Human Clone 0365-0001-8174 ?4-Chain) Disulfide With Human Clone 0365-0001-8174 ?-Chain | Novo Nordisk A/S | P3 | BBB |
| bay94-9027 | Bayer | P4 | BBB |
| N8-GP | Novo Nordisk A/S | P3 | BBB |
| Emicizumab | Emory University | P4 | BBB |
| Fitusiran | Sanofi | P4 | BBB |
+36 more in the Hemophilia A cohort
Other indications for Coagulation Factor Viia Variant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hemophilia B | — | P2 | CCC · 55 |
| Factor VII Deficiency | — | P1/2 | CCC · 48 |
| Glanzmann Thrombasthenia | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Turoctocog AlfaNovo Nordisk A/SA
- Eptacog Alfa (Activated)AryoGen Pharmed Co.A
- Rurioctocog Alfa PegolTakedaBBB
- Immunoglobulin G4 [230-Proline,De-449-Lysine], Anti-(Human Blood-Coagulation Factor Ix)(Human Clone 0365-0001-9985 ?4-Chain), Disulfide With Human Clone 0365-0001-9985 ?-Chain, (228?226?),(231?229?)-Bis(Disulfide) With Anti-(Human Blood-Coagulation Factor X) Immunoglobulin G4 [228-Proline,405-Leucine,409-Lysine,De-447-Lysine] (Human Clone 0365-0001-8174 ?4-Chain) Disulfide With Human Clone 0365-0001-8174 ?-ChainNovo Nordisk A/SBBB
- bay94-9027BayerBBB
Citation
Floatz Terminal. Coagulation Factor Viia Variant in Hemophilia A. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/coagulation-factor-viia-variant-hemophilia-a
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →